A securities class action has been initiated against Vistagen Therapeutics Inc. (VTGN) alleging the company made materially misleading statements regarding its fasedienol drug candidate while omitting significant adverse information from investors. The lawsuit centers on disclosures related to the PALISADE-3 clinical trial, with the complaint contending that investors were not adequately informed of unfavorable trial developments during the relevant period.
Investors who acquired VTGN shares between April 1, 2024 and December 16, 2025 may have grounds to participate in the class action. Lead plaintiff nominations must be submitted by March 16, 2026, establishing a critical timeline for eligible shareholders seeking to secure legal representation. Class members are urged to consult with securities counsel to evaluate their eligibility and understand the implications of available options.
The litigation represents one of several mechanisms through which shareholders can pursue recovery for losses attributed to alleged disclosure violations. Interested parties should review case documents and consult qualified legal advisors to determine appropriate courses of action before the approaching deadline.